Difelikefalin clinical trials
Also written CR845 and MR13A9.
How each study uses difelikefalin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the difelikefalin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 23 Aug 2021 · KORSUVA · NDA 214916 (FDA, Drugs@FDA)
- European Union
- 25 Apr 2022 · Kapruvia · EMEA/H/C/005612 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
28 studies that test it; most in 2019 (7)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 7 |
| 2021 | 2 |
| 2022 | 3 |
| 2023 | 3 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 27 · Other 1
Cara Therapeutics, Inc. (22) · Vifor Fresenius Medical Care Renal Pharma (3) · Kissei Pharmaceutical Co., Ltd. (2) · Chittagong Medical College (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test difelikefalin.
- Jan 2027Difelikefalin for Itching in Hemodialysis Patients With Chronic Kidney DiseaseNot applicable · Chittagong Medical College
Studies
Open first, then newest update. How each study uses difelikefalin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 28
- Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe PruritusRecruitingPhase 2Vifor Fresenius Medical Care Renal PharmaNCT06593392Written as Difelikefalin
- Difelikefalin for Itching in Hemodialysis Patients With Chronic Kidney DiseaseNot yet recruitingNot applicableChittagong Medical CollegeNCT07526324Written as Difelikefalin Injection
- A Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus.CompletedPhase 2Kissei Pharmaceutical Co., Ltd.NCT03802617Written as MR13A9
- Phase 3 Study of Difelikefalin in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe PruritusCompletedPhase 3Vifor Fresenius Medical Care Renal PharmaNCT05885737Written as Difelikefalin Injection
- A Phase III Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus.CompletedPhase 3Kissei Pharmaceutical Co., Ltd.NCT04711603Written as MR13A9
- Pharmacokinetics of Intravenous Difelikefalin in Chinese Adult Subjects on HaemodialysisCompletedPhase 1Vifor Fresenius Medical Care Renal PharmaNCT05885763Written as Difelikefalin Injection
- Study to Evaluate the Efficacy and Safety of Oral Difelikefalin for Moderate to Severe Pruritus in Subjects With Notalgia ParestheticaTerminatedPhase 2/3Cara Therapeutics, Inc.NCT05978063Written as difelikefalin 2.0 mg tablets
- CR845-310302: A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe PruritusTerminatedPhase 3Cara Therapeutics, Inc.NCT05356403Written as Difelikefalin 1 mg Oral Tablet
- A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe PruritusTerminatedPhase 3Cara Therapeutics, Inc.NCT05342623Written as Difelikefalin 1 mg Oral Tablet
- Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic DermatitisTerminatedPhase 3Cara Therapeutics, Inc.NCT05387707Written as difelikefalin 0.25 mg
- A Study to Evaluate the Safety and Efficacy of CR845 in Chronic Kidney Disease Patients With Moderate-to-Severe PruritusCompletedPhase 2Cara Therapeutics, Inc.NCT03617536Written as CR845 0.25 mg Oral Tablet
- Study to Evaluate the Safety and Efficacy of Oral CR845 (Difelikefalin) in Patients With Primary Biliary Cholangitis (PBC) and Moderate-to-Severe PruritusTerminatedPhase 2Cara Therapeutics, Inc.NCT03995212Written as CR845 1.0 mg
- Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica (KOMFORT)CompletedPhase 2Cara Therapeutics, Inc.NCT04706975Written as difelikefalin 2.0 mg
- CR845-100303: Study to Assess the Potential of Physical Withdrawal From Intravenous CR845 (Difelikefalin) in Hemodialysis PatientsCompletedPhase 1Cara Therapeutics, Inc.NCT05533008Written as CR845 0.5 mcg/kg
- CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe PruritusCompletedPhase 3Cara Therapeutics, Inc.NCT03636269Written as CR845 0.5 mcg/kg
- A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1)CompletedPhase 3Cara Therapeutics, Inc.NCT03422653Written as CR845 0.5 mcg/kg
- Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Atopic DermatitisCompletedPhase 2Cara Therapeutics, Inc.NCT04018027Written as difelikefalin 0.25 mg
- CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe PruritusCompletedPhase 3Cara Therapeutics, Inc.NCT03998163Written as CR845 0.5 mcg/kg
- Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe PruritusCompletedPhase 3Cara Therapeutics, Inc.NCT03281538Written as CR845
- A Study Evaluating Pain Relief and Safety of Orally Administered CR845 in Patients With Osteoarthritis of Hip or KneeCompletedPhase 2Cara Therapeutics, Inc.NCT02944448Written as CR845 tablet 1 mg
See all 28 studies that test difelikefalin →
As the comparator · 1 — what is tested is compared with difelikefalin
Codes
What other systems call difelikefalin · ClinicalTrials.gg INT001262
- MeSH (NLM) C000657129difelikefalinConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) NA1U919MRODIFELIKEFALINConfirmed FDA, NLM, Wikidata
- RxNorm 2569089One source FDA
- Wikidata Q21098992difelikefalinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C174752DifelikefalinOne source FDA
- DrugBank DB11938One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000657129 | difelikefalin | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | NA1U919MRO | DIFELIKEFALIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2569089 | — | One source FDA |
| Wikidata | Q21098992 | difelikefalin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C174752 | Difelikefalin | One source FDA |
| DrugBank | DB11938 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.